Wilms tumor is an embryonal kidney cancer of children that has been linked to molecular genetic abnormalities on the short arm of chromosome 11. This tumor is associated with anomalies in the urogenitary system and a shared genetic origin has become evident from the cloning and characterization of the WT1 locus by ourselves and others. WT1 is restricted in expression to the condensing metanephric mesenchyme or developing glomeruli. Thus it must respond to induction signals following interaction of the metanephric mesenchyme and the epithelial ureteric bud and likely regulate the expression of other genes involved in differentiation and morphogenesis. The long term objective of this project is to determine how the WT1 regulates this process by identifying WT1-target genes and defining their role in nephrogenesis and tumorigenesis. These objectives will be achieved by pursuing the following specific aims. To test the hypothesis that WT1 both activates and represses target genes to regulate nephrogenesis in Aim one we will characterize genes identified as potential WT1 targets from GeneChip analyses by studying their promoters, examining their expression in Wilms tumors and during nephrogenesis in vitro and in vivo.
In aim two we will use chromatin precipitation to identify genes that are direct transcriptional targets for WT1.
In aim three we will modulate WT1 and p53 expression in a Wilms tumor cell line and determine effects on transcript profiles. We will also develop kidney specific cDNA arrays and methods for specifically ablating selective transcripts. The proposed studies promise to provide new insights into the role of WT1 as a transcriptional regulator and to lead to the identification of novel genes involved in nephrogenesis and Wilms tumorigenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA089279-04
Application #
6802921
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Mietz, Judy
Project Start
2001-08-23
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2005-06-30
Support Year
4
Fiscal Year
2003
Total Cost
$276,390
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Graham, Kylie; Li, Wenliang; Williams, Bryan R G et al. (2006) Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells. Gene Expr 13:1-14
Li, Wenliang; Kessler, Patricia; Yeger, Herman et al. (2005) A gene expression signature for relapse of primary wilms tumors. Cancer Res 65:2592-601
Li, Wenliang; Kessler, Patricia; Williams, Bryan R G (2005) Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene 24:457-68
Jackson, Mark W; Agarwal, Mukesh K; Agarwal, Munna L et al. (2004) Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene 23:4477-87
Alami, J; Williams, B R; Yeger, H (2003) Differential expression of E-cadherin and beta catenin in primary and metastatic Wilms's tumours. Mol Pathol 56:218-25
Alami, Jennifer; Williams, Bryan R; Yeger, Herman (2003) Derivation and characterization of a Wilms' tumour cell line, WiT 49. Int J Cancer 107:365-74